Diabetes: preventing coronary heart disease in a high risk group

被引：11

作者：

Feher, MD ^{[1
]}

机构：

[1] Chelsea & Westminster Hosp, Beta Cell Diabet Ctr, London SW10 9NH, England

来源：

HEART | 2004年 / 90卷

关键词：

D O I：

10.1136/hrt.2004.037572

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Cardiovascular disease is the major cause of morbidity and mortality in patients with type 2 diabetes. Numerous outcome trials have demonstrated clinical benefits from effective treatment of individual cardiovascular risk factors in patients with diabetes. These trials have provided the basis for current treatment guidelines and targets. More recently, multifactorial intervention strategies have shown a reduction in both cardiovascular and microvascular events in patients with type 2 diabetes. However, full implementation of a truly multifactorial strategy into routine practice remains an ideal due to practical difficulties of sustained implementation and associated costs. These practical issues relating to the treatment of diabetes and its complications are now in a greater spotlight due to the growing number of patients requiring treatment.

引用

页码：18 / 21

页数：4

共 25 条

[1] Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study [J].

Adler, AI ;

Stratton, IM ;

Neil, HAW ;

Yudkin, JS ;

Matthews, DR ;

Cull, CA ;

Wright, AD ;

Turner, RC ;

Holman, RR .

BMJ-BRITISH MEDICAL JOURNAL, 2000, 321 (7258) :412-419

[2] Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].

Chobanian, AV ;

Bakris, GL ;

Black, HR ;

Cushman, WC ;

Green, LA ;

Izzo, JL ;

Jones, DW ;

Materson, BJ ;

Oparil, S ;

Wright, JT ;

Roccella, EJ .

HYPERTENSION, 2003, 42 (06) :1206-1252

[3]

Collins R, 2003, LANCET, V361, P2005

[4] Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS [J].

Downs, JR ;

Clearfield, M ;

Weis, S ;

Whitney, E ;

Shapiro, DR ;

Beere, PA ;

Langendorfer, A ;

Stein, EA ;

Kruyer, W ;

Gotto, AM .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20) :1615-1622

[5]

FISHER M, 2003, HEART, V89, P28, DOI DOI 10.1136/HEART.89.SUPPL_2.II28

[6] Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes [J].

Gaede, P ;

Vedel, P ;

Larsen, N ;

Jensen, GVH ;

Parving, H ;

Pedersen, O .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (05) :383-393

[7] Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels -: Subgroup analyses in the cholesterol and recurrent events (CARE) trial [J].

Goldberg, RB ;

Mellies, MJ ;

Sacks, FM ;

Moyé, LA ;

Howard, BV ;

Howard, WJ ;

Davis, BR ;

Cole, TG ;

Pfeffer, MA ;

Braunwald, E .

CIRCULATION, 1998, 98 (23) :2513-2519

[8] Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels -: Subgroup analyses in the Scandinavian simvastatin survival study [J].

Haffner, SM ;

Alexander, CM ;

Cook, TJ ;

Boccuzzi, SJ ;

Musliner, TA ;

Pedersen, TR ;

Kjekshus, J ;

Pyörälä, K .

ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (22) :2661-2667

[9] Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:: principal results of the hypertension optimal treatment (HOT) randomised trial [J].

Hansson, L ;

Zanchetti, A ;

Carruthers, SG ;

Dahlöf, B ;

Elmfeldt, D ;

Julius, S ;

Ménard, J ;

Rahn, KH ;

Wedel, H ;

Westerling, S .

LANCET, 1998, 351 (9118) :1755-1762

[10]

Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512

← 1 2 3 →